These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Author: Schröder U, Schröder H, Augustin W, Sabel BA.
    Journal: J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425.
    Abstract:
    In rats, dopamine supersensitivity was induced by haloperidol (HAL) treatment for 3 weeks, either by implanted polymer matrices or by daily i.p. injections (1.0 mg/kg/day). Thereafter, dopamine supersensitivity was tested by measurement of motor activity of the animals after application of the dopamine agonist apomorphine (0.5 mg/kg i.p.) and by determination of the specific D2 dopamine binding sites in the corpus striatum by using [3H]spiroperidol. In both modes of HAL administration, no differences were found in the behavioral and neurochemical parameters. The apomorphine-induced motility was enhanced, and the known up-regulation of the striatal D2 dopamine binding was detected. When monosialoganglioside (GM1) was given daily i.p. for 3 weeks parallel to HAL application, dopamine supersensitivity, as indicated by the apomorphine-induced motility, was enhanced significantly without affecting the striatal D2 dopamine receptor up-regulation. In a subsequent experiment, we reduced the HAL dose and observed the expected D2 dopamine up-regulation. However, GM1 had no effect either on striatal D2 dopamine binding or on motility. A thin-layer chromatography analysis revealed that the endogenous gangliosides pattern in the corpus striatum also remained unchanged after HAL treatment. In conclusion, GM1-induced elevation of behavioral supersensitivity cannot be explained by a direct interaction with the D2 dopamine receptor, but other mechanisms may be involved, such as the modification of second messenger pathways.
    [Abstract] [Full Text] [Related] [New Search]